SG Americas Securities LLC Has $1.26 Million Stock Holdings in Agilent Technologies, Inc. $A

SG Americas Securities LLC reduced its position in Agilent Technologies, Inc. (NYSE:A) by 36.2% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 10,644 shares of the medical research company’s stock after selling 6,052 shares during the period. SG Americas Securities LLC’s holdings in Agilent Technologies were worth $1,256,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in A. Vanguard Group Inc. increased its position in Agilent Technologies by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company’s stock worth $3,908,141,000 after purchasing an additional 240,965 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Agilent Technologies by 10.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company’s stock valued at $1,560,964,000 after purchasing an additional 1,273,994 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Agilent Technologies by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 7,319,530 shares of the medical research company’s stock valued at $860,137,000 after purchasing an additional 115,183 shares during the last quarter. Generation Investment Management LLP grew its position in shares of Agilent Technologies by 15.9% during the 2nd quarter. Generation Investment Management LLP now owns 5,775,860 shares of the medical research company’s stock worth $681,609,000 after buying an additional 792,304 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Agilent Technologies by 18.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock worth $448,748,000 after buying an additional 604,124 shares during the last quarter. Institutional investors own 87.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on A shares. TD Cowen raised their price objective on shares of Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. JPMorgan Chase & Co. increased their price target on Agilent Technologies from $155.00 to $165.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Robert W. Baird lifted their price objective on Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, August 28th. UBS Group upgraded Agilent Technologies from a “neutral” rating to a “buy” rating and upped their price objective for the company from $130.00 to $170.00 in a report on Wednesday, October 8th. Finally, Rothschild & Co Redburn initiated coverage on Agilent Technologies in a report on Wednesday, October 8th. They set a “buy” rating and a $165.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $149.62.

Insiders Place Their Bets

In other news, CEO Padraig Mcdonnell sold 12,490 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total value of $1,873,500.00. Following the completion of the transaction, the chief executive officer owned 33,448 shares in the company, valued at $5,017,200. This represents a 27.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.26% of the company’s stock.

Agilent Technologies Stock Performance

Shares of Agilent Technologies stock opened at $151.49 on Friday. The stock’s fifty day simple moving average is $139.65 and its 200 day simple moving average is $125.10. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $42.95 billion, a PE ratio of 35.56, a PEG ratio of 4.67 and a beta of 1.29. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company’s revenue was up 10.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, research analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 6th will be issued a dividend of $0.255 per share. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.25. The ex-dividend date is Tuesday, January 6th. This represents a $1.02 annualized dividend and a yield of 0.7%. Agilent Technologies’s dividend payout ratio is 23.94%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.